Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma (NAMS) EPS (Basic) (2023 - 2025)

NewAmsterdam Pharma's EPS (Basic) history spans 3 years, with the latest figure at -$0.62 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 34.74% year-over-year to -$0.62; the TTM value through Dec 2025 reached -$1.72, up 33.33%, while the annual FY2025 figure was -$1.72, 32.81% up from the prior year.
  • EPS (Basic) for Q4 2025 was -$0.62 at NewAmsterdam Pharma, down from -$0.61 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.15 in Q2 2025 and bottomed at -$1.06 in Q1 2024.
  • The 3-year median for EPS (Basic) is -$0.54 (2023), against an average of -$0.54.
  • The largest annual shift saw EPS (Basic) surged 68.42% in 2024 before it plummeted 238.89% in 2025.
  • A 3-year view of EPS (Basic) shows it stood at -$0.6 in 2023, then tumbled by 58.33% to -$0.95 in 2024, then surged by 34.74% to -$0.62 in 2025.
  • Per Business Quant, the three most recent readings for NAMS's EPS (Basic) are -$0.62 (Q4 2025), -$0.61 (Q3 2025), and -$0.15 (Q2 2025).